Your Online Health Information Site


What’s New With Prostate Cancer

What’s new with prostate cancer is reviewed here where recent literature regarding prostate cancer has been reviewed.

There are a total of 156 differentially expressed genes that code for human prostate cancer, according to Ref. 4. The “E2F4” gene is one of the major players for the epithelial tumor cells. The “Daxx” gene is found more in tumor stroma. The authors feel that much can be learnt from further study of the expression of these genes.

This will open new doors for innovative prostate cancer treatments.

How can impotence as a result of radiotherapy be prevented? Ref. 5 has the answer:

These authors found that too much unnecessary radiation to the bulb of the penis (the root of the swelling bodies at the inside end of the penis) is to be blamed for impotence after radiation for prostate cancer. By changing the configuration of the crossing beams and sparing the bulb of the penis the impotence rate and severity can be reduced. At the same time the cure rates for prostate cancer are unaffected!

Is it true or false that age has an influence on the behavior of prostate cancer? The answer can be found in Ref. 5: Age does not play any significant factor in tumor behavior, however, the tumor stage does. As a man ages, testosterone levels fall and often progesterone levels as well and this can be measured with saliva testing, which mirrors the tissue levels of these hormones. The lower these hormones are, the more aggressive the prostate cancer will be. This is research coming from Harvard trained Dr. Morgentaler (Ref. 12). Bio-identical hormone replacement with topical creams helps prevent prostate cancer.

A new endonuclease, called Ukrain (thanks to for this link) is a specific chemotherapeutic agent, which is much less toxic than the usual chemotherapeutic agents.

What’s New With Prostate Cancer (Greater Celandine)

What’s New With Prostate Cancer (Greater Celandine)

Ref. 7 describes a retrospective study where out of a group of 20 patients with prostate cancer 70% experienced a total remission and another 25% a partial remission of their prostate cancer. However, as encouraging as this study might sound, a well designed phase III clinical trial with proper placebo controls and a prospective set-up needs to be done to verify these findings and to establish the optimal dosage for this new therapy with Ukrain.

Deception of “what’s new”?

When I read medical news releases and articles in the latest medical journals, I am aware that there are major interest groups that want to sell their products. Nothing has changed since the publications of Dr. Lee (Ref. 11), Dr. Morgentaler (Ref. 12) and Dr. Platt (Ref.10). The new world picture of prostate cancer is that there is a hormone dysbalance with too much estrogen (estradiol) from fatty tissue (overweight and obese men) and a lack of testosterone and of progesterone production (age-related). Testosterone strengthens the heart, the brain and the sexual organs and also counters the effect of estrogen provided it is present in the saliva hormone test with a 20-fold or higher concentration than estradiol. In this sense testosterone has a prostate and other cancer preventative function. This goes against the establishment of urologists, cancer clinics and many other physicians, but has been shown in countless publications (summarized in Ref. 12). The “news” is the fact that old prejudices are still not overcome and this is the reason that there has not been a major breakthrough in prostate cancer prevention other than the new bio-identical approach described under treatment of prostate cancer. Add to this that 5000 IU of vitamin D3 per day will reduce the risk for prostate Cancer by 50% or more (Ref. 13, 14) and there you have what is really new with prostate cancer.

ENOX-2 gene: This gene is a gene expressed only throughout embryonic life. Later in life it becomes only expressed when cancer develops. It can be used as an early test to detect cancer, including prostate cancer 6 to 8 years before cancer can be detected clinically. For more info see:


The following references were used apart from my own clinical experience:

1. Cancer: Principles &Practice of Oncology, 4th edition, by V.T. De Vita,Jr.,et. al J.B. LippincottCo.,Philadelphia, 1993.Vol.1: Chapter on Prostate cancer.

2. The Merck Manual, 7th edition, by M. H. Beers et al., Whitehouse Station, N.J., 1999.Chapter 233, p.1918-1919.

3. Cancer: Principles&Practice of Oncology. 5th edition, volume 1. Edited by Vincent T.DeVita, Jr. et al. Lippincott-Raven Publ., Philadelphia,PA, 1997. Chapter on prostate cancer.

4. A Waghray et al. Cancer Res 2001 May 15;61(10):4283-4286.

5. BM Fisch et al. Urology 2001 May;57(5):955-959.

6. CC Parker et al. BJU Int 2001 May;87(7):629-637.

7. B Aschhoff Drugs Exp Clin Res 2000;26(5-6):249-252.

8. Conn’s Current Therapy 2004, 56th ed., Copyright © 2004 Elsevier

9. Ferri: Ferri’s Clinical Advisor: Instant Diagnosis and Treatment, 2004 ed., Copyright © 2004 Mosby, Inc

10. Michael E. Platt: “The Miracle of Bio-identical Hormones” © 2007, Clancy Lane Publishing, Rancho Mirage, California, USA ; pages 111-113.

11. John R. Lee: “Hormone Balance for Men – What your Doctor May Not Tell You About Prostate Health and Natural Hormone Supplementation”, © 2003 by Hormones Etc.

12. Abraham Morgentaler, MD “Testosterone for Life – Recharge your vitality, sex drive, muscle mass and overall health”, McGraw-Hill, 2008


Last modified: July 25, 2022

This outline is only a teaching aid to patients and should stimulate you to ask the right questions when seeing your doctor. However, the responsibility of treatment stays in the hands of your doctor and you.